Biogen Reports Second Quarter 2022 Results

Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Biogen Inc.  (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System

Biogen to Participate in the Stifel 2023 CNS Days

Cambridge, MA, - -  Biogen Inc.   (Nasdaq: BIIB) announced today that Priya Singhal, M.D., M.P.H., Head of Development, will participate in the Stifel 2023 CNS Days. The webcast will be live on Tuesday, March 28, 2023, at 9:15 a.m. ET. To access the live webcast, please visit the Investors section